Literature DB >> 30682399

Bridging the gaps between academic research and industrial product developments of lipid-based formulations.

René Holm1.   

Abstract

Lipid-based formulations, including self-emulsifying drug delivery systems (SEDDS), are an interesting formulation technology that enables the clinical use of compounds for which a low aqueous solubility may be a limitation. From an academic perspective, the technology is interesting on several levels: what drives solubility, what determines bioperformance, what is the potential for solidification etc. From an industrial perspective, >35 lipid-based formulations are available and there is an unknown number of projects in the pipeline. Hence, while there is scientific interest from both academic and industrial perspectives, the agendas/needs in the two settings are different. From an industrial perspective, risks are associated with uncertainty; hence the more that is known about a technology the better - knowledge that in principle can be generated in both the academia and industry. This focuses on the development of lipid-based formulations and the knowledge gaps that could be investigated -with the hope that all stakeholders in the field of lipid-based formulations, including academia, industry, CRO's, lipid excipient manufacturers etc., would share their insight, so that this technology can be even further developed. Some of the gaps discussed include the selection of compounds suited for lipid-based formulations, which potential modifications that could be investigated, e.g., lipophilic salts, what is a relevant definition of accelerated stability studies, how best to construct an industrial development program of a lipid-based formulation, etc.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Industrialisation; Lipid-based formulations; Liquid filled capsules; SEDDS

Mesh:

Substances:

Year:  2019        PMID: 30682399     DOI: 10.1016/j.addr.2019.01.009

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  6 in total

Review 1.  Oxidative Stability in Lipid Formulations: a Review of the Mechanisms, Drivers, and Inhibitors of Oxidation.

Authors:  Jasmine Musakhanian; Jean-David Rodier; Masumi Dave
Journal:  AAPS PharmSciTech       Date:  2022-05-20       Impact factor: 3.246

Review 2.  Fundamental Aspects of Lipid-Based Excipients in Lipid-Based Product Development.

Authors:  Deepa Nakmode; Valamla Bhavana; Pradip Thakor; Jitender Madan; Pankaj Kumar Singh; Shashi Bala Singh; Jessica M Rosenholm; Kuldeep K Bansal; Neelesh Kumar Mehra
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

3.  Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure.

Authors:  Erin Tay; Tri-Hung Nguyen; Leigh Ford; Hywel D Williams; Hassan Benameur; Peter J Scammells; Christopher J H Porter
Journal:  Pharmaceutics       Date:  2019-12-22       Impact factor: 6.321

4.  In-Silico Screening of Lipid-Based Drug Delivery Systems.

Authors:  Joscha Brinkmann; Lara Exner; Christian Luebbert; Gabriele Sadowski
Journal:  Pharm Res       Date:  2020-11-23       Impact factor: 4.200

5.  Nanoporous Silica Entrapped Lipid-Drug Complexes for the Solubilization and Absorption Enhancement of Poorly Soluble Drugs.

Authors:  Hey-Won Shin; Joo-Eun Kim; Young-Joon Park
Journal:  Pharmaceutics       Date:  2021-01-06       Impact factor: 6.321

6.  Improved Trimethylangelicin Analogs for Cystic Fibrosis: Design, Synthesis and Preliminary Screening.

Authors:  Christian Vaccarin; Daniela Gabbia; Erica Franceschinis; Sara De Martin; Marco Roverso; Sara Bogialli; Gianni Sacchetti; Chiara Tupini; Ilaria Lampronti; Roberto Gambari; Giulio Cabrini; Maria Cristina Dechecchi; Anna Tamanini; Giovanni Marzaro; Adriana Chilin
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.